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Abstract
Background: Opioid analgesics have proven efficacy in the short-term management of chronic cancer
pain, but data on their long-term use is more limited. OROS® hydromorphone is a controlled-release
formulation of oral hydromorphone that may be particularly well suited to long-term management of
chronic cancer pain because it provides stable plasma concentrations and consistent analgesia with
convenient once-daily dosing. The objective of this study (DO-118X) was to characterise the pain control
achieved with long-term repeated dosing of OROS® hydromorphone in patients with chronic cancer pain.
Methods: In this multicentre, phase III, open-label, single treatment, 1-year extension study, OROS®
hydromorphone was administered to 68 patients with moderate-to-severe chronic cancer pain, who had
successfully completed a short-term equivalence study, and whose pain was controlled with a stable dose
of medication (≥ 8 mg OROS® hydromorphone or equivalent controlled-release morphine). Patients were
started on the dose of OROS® hydromorphone equivalent to the opioid dose on which they achieved
dose-stable pain control in the equivalence study; dose adjustments were made as necessary and
breakthrough pain medication was permitted. Efficacy was assessed with the Brief Pain Inventory (BPI) and
patient and investigator global evaluations of treatment effectiveness. No formal statistical analysis was
done.
Results: The mean (standard deviation) duration of exposure to study medication was 139 (129.9) days
and the mean (standard deviation) average daily consumption of OROS® hydromorphone was 43.7 (28.14)
mg/day. All scores were maintained at a mild to moderate severity throughout the study; however, BPI
scores for pain at its worst, pain at its least, pain on average, pain right now, and pain relief were slightly
worsened at end point compared with baseline. Mean BPI pain interference with daily activities and patient
and investigator global evaluation scores also remained generally stable. Treatment effectiveness was rated
as fair to good throughout the study. The most frequently reported adverse events were nausea (n = 24,
35.3%), constipation (n = 22, 32.4%), and vomiting (n = 15, 22.1%).
Conclusion: The results of this extension study suggest that long-term repeated dosing with once-daily
OROS® hydromorphone can be beneficial in the continuing management of persistent, moderate-to-
severe cancer pain.
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Background
Chronic severe pain is a common complication of cancer
[1]. Opioid analgesics are highly effective at treating can-
cer pain and are typically used after maximum doses of
non-opioid analgesics have failed [2-5]. The European
Association for Palliative Care [6] and the American Pain
Society [7] support the use of long-term analgesics for
maintaining pain relief once individual dose require-
ments have been established.
Hydromorphone hydrochloride is a hydrogenated semi-
synthetic potent μ-opioid agonist that has been used for
many years to treat moderate-to-severe cancer pain.
Numerous studies have demonstrated an efficacy and
safety profile similar to that of morphine and other opio-
ids [8-10]. For oral administration, it is available as short-
acting immediate-release (IR) and long-acting controlled-
release (CR). OROS® hydromorphone (Jurnista™; Janssen
Pharmaceutica, Beerse, Belgium) is a novel, once-daily,
CR formulation of oral hydromorphone which uses a pat-
ented Push-Pull™ osmotically-controlled pump system
(ALZA Corporation, Mountain View, CA, USA) to release
hydromorphone in a continuous monophasic manner for
up to 24 hours. It is an important treatment option for
patients with chronic pain as it provides consistent pain
relief, convenient once-daily dosing, and can reduce opi-
oid-related adverse effects and breakthrough pain associ-
ated with peak and trough fluctuations in plasma
concentrations typically seen with IR formulations
[11,12]. OROS® hydromorphone is currently available in
4, 8, 16, 32, and 64 mg tablets.
The pharmacokinetic (PK) properties of OROS® hydro-
morphone demonstrate that hydromorphone is released
in a consistent manner from the dosage form. Plasma
hydromorphone concentrations peak significantly later
(12-18.0 hours versus 0.8 hours) but are maintained sig-
nificantly longer at greater than 50% of peak concentra-
tion (22.7 hours versus 1.1 hours) with OROS®
hydromorphone than with IR hydromorphone [13]. The
plasma concentrations achieved after OROS® hydromor-
phone administration reach approximately 80% of the
peak concentration within 6-8 hours and remain elevated
until approximately 18-24 hours post-dose [12]. The
mean absolute bioavailability of hydromorphone after a
single dose of 8, 16, or 32 mg of OROS® hydromorphone
ranged from 22% to 26%. Clinical PK analysis has shown
a consistent release of hydromorphone over 24 hours,
with steady-state plasma concentrations achieved by 48
hours (2 doses) and sustained throughout the 24-hour
dosing interval [14,15]. Further research has confirmed
that the PK of OROS® hydromorphone are linear and
dose-proportional across the available doses [16]. The
apparent terminal half-life of OROS® hydromorphone is
10-11 hours [16]. A close relationship between plasma
concentration and analgesic activity has been described
for OROS® hydromorphone [13].
An osmotically-controlled system means that release of
the drug from the system is not significantly affected by
environmental factors such as pH or gastric motility [17].
There is a minimal effect of food on the rate and extent of
absorption of hydromorphone from OROS® hydromor-
phone [18], and the PK are not significantly affected by
alcohol, with no evidence of 'dose dumping' of hydro-
morphone [19]. In addition, conversion from previous
standard opioid therapy to OROS® hydromorphone can
be achieved without loss of pain control or increase in
adverse events (AEs) in patients with chronic malignant
[20,21] and non-malignant pain [22].
The safety and tolerability of hydromorphone is well
established, with a side effect profile similar to that of
other opioid analgesics (mild to moderate constipation,
dizziness, nausea, and vomiting). Analyses of the oral IR
formulation in special populations concluded that gender
does not affect the PK of hydromorphone [23]; however,
mean peak concentration (Cmax) was decreased by 14%
and overall exposure (AUC) was increased by 11% in eld-
erly (aged 65-74 years) compared with younger (aged 18-
38 years) patients receiving single doses of hydromor-
phone [24]. For this reason, it is advised that the treat-
ment of the elderly with hydromorphone should be
cautious and the initial dose should be reduced [15].
Hydromorphone has been found to be safe and effective
in patients with impaired renal or hepatic function,
although it is advised to be used with caution and close
monitoring owing to the increased exposure to (mean
Cmax and AUC were 2- to 4-fold higher) and slower elimi-
nation of hydromorphone and its metabolites in these
patients [25-29].
Glucuronidation is the main metabolic pathway of hydro-
morphone and the principal metabolite is hydromor-
phone-3-glucuronide. It is unlikely that hydromorphone
would be involved in drug interactions involving cyto-
chrome P450 (CYP) because studies have shown hydro-
morphone is metabolised via non-CYP dependent
pathways and only minimally metabolised by P450
enzymes [30,31]. Hydromorphone also lacks the analge-
sically active metabolites of many opioids that may lead
to respiratory depression if accumulated and demon-
strates a very low plasma protein binding (< 30%)
[32,33]. For these reasons OROS® hydromorphone may
be especially suitable and predictable for elderly patients,
patients with renal or hepatic insufficiency, and patients
with multiple morbidities and medications.
Two recent studies have compared OROS®  hydromor-
phone to other commonly used opioid analgesics: CRBMC Palliative Care 2009, 8:14 http://www.biomedcentral.com/1472-684X/8/14
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morphine [34] and extended-release (ER) oxycodone
[35]. In patients with cancer pain, clinical equivalence in
terms of Brief Pain Inventory (BPI) scores for 'worst pain
in the past 24 hours' was not demonstrated for OROS®
hydromorphone and CR morphine. However, the nega-
tive direction of the mean difference between the treat-
ments was in favour of OROS®  hydromorphone and
comparable results were found for secondary efficacy
measures such as assessments of pain interference with
daily activities [34]. With OROS® hydromorphone, pain
intensity scores were similar in the morning and evening
(measured by BPI pain now AM and PM), and pain levels
in the evening were significantly lower with OROS®
hydromorphone compared with CR morphine. This con-
firms that OROS® hydromorphone provides consistent
pain relief over 24 hours and that there is little end-of-
dose failure pain. The half value duration (the time period
in which the plasma level of the active ingredient is over
the half-maximum concentration) can be used to measure
the prolongation of the duration of action of CR prepara-
tions and therefore test for end-of-dose failure pain; the
half value duration of OROS® hydromorphone is between
27 and 29 hours [36]. In the second comparative study,
once-daily OROS® hydromorphone and twice-daily ER
oxycodone provided comparable levels of pain relief and
reductions in pain severity, as well as improvements in
investigator and patient global evaluation scores and sub-
jective measures of daily function and sleep, in patients
with chronic, moderate to severe osteoarthritis pain [35].
In both studies, AEs were comparable between treatments
and typical of opioid analgesic therapy.
Although opioids have proven efficacy in the manage-
ment of chronic moderate-to-severe pain, data on their
long-term use is limited, as most research has used rela-
tively short-term studies [37-39]. This issue has become
progressively more important in recent years as the life
expectancy of cancer patients increases owing to improved
oncological therapies. As a result, long-term opioid use in
cancer patients has become widespread, and therefore
data on the safety and efficacy of long-term exposure is
necessary [37-42]. This study was an extension study for
patients successfully completing a previous equivalence
study, which was a randomised, double blind study to test
the clinical equivalence of IR and CR formulations of
hydromorphone and morphine in 200 adult patients with
chronic moderate-to-severe cancer pain [34]. The primary
objective of this extension study was to characterise the
pain control achieved with long-term repeated dosing, for
up to 1 year, of OROS® hydromorphone in patients with
chronic cancer pain.
Methods
The study (DO-118X) was approved by the independent
ethics committee appropriate to each participating centre
before any patients were enrolled at that centre, and was
conducted in accordance with the recommendations of
the Declaration of Helsinki and the European Commu-
nity Commission Directive 91/507/EEC by adopting the
Good Clinical Practice (GCP) principles as defined in the
International Conference on Harmonisation (ICH) guide-
lines for GCP (CPMP/ICH/135/95). All patients gave writ-
ten informed consent before entering the study.
Patients
The study enrolled adult (≥ 18 years of age) patients with
chronic cancer pain, who had completed the randomised,
double blind equivalence study, and whose pain was con-
trolled with a stable dose of study medication, ≥ 8 mg/day
of either OROS® hydromorphone or an equivalent CR
morphine sulphate dose, during the final 2 days of the CR
phase of the equivalence study. The criteria used for
patient selection are listed in Table 1. It was planned to
include up to 140 patients.
Study design
This was a phase III, multicentre, open-label, single treat-
ment arm, 1-year extension study. It was conducted at 17
centres in Europe and Canada.
The screening process for patients entering the study was
their participation in and completion of the previous
equivalence study. Patients then completed a baseline
visit (visit 1), which was also the final visit in the equiva-
lence study, during which, the inclusion and exclusion cri-
teria were reviewed, a physical examination was done, the
BPI was administered, and the study drug was dispensed.
All patients received the same treatment, OROS® hydro-
morphone. Patients were started on a dose of OROS®
hydromorphone equivalent to the opioid dose on which
they had achieved dose-stable pain control in the CR
phase of the equivalence study (using a 5:1 conversion
ratio of morphine sulphate to hydromorphone hydro-
chloride [43-46]). Dose adjustments, to be made after 2
days of therapy at a dose level, were then made as needed,
based on the patient's degree of opioid tolerance, general
condition and medical status, concurrent medication,
type and severity of pain, and the amount and frequency
of rescue medication needed for breakthrough pain. Dose
increases were to be generally in 8 mg increments for
patients receiving total daily doses of up to 32 mg and 16
mg increments in patients receiving doses of greater than
32 mg/day. IR hydromorphone 2 and 4 mg tablets were
dispensed for breakthrough pain. The maximum daily
dose of rescue medication was not to exceed 10-15% of
the daily OROS® hydromorphone dosage.
The treatment phase of the study lasted for up to 1 year,
during which time patients returned to the clinic atBMC Palliative Care 2009, 8:14 http://www.biomedcentral.com/1472-684X/8/14
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monthly intervals for assessment. During these monthly
evaluations, any unused study medication was collected
and new medication was dispensed, the BPI and global
evaluations of overall medication effectiveness were
administered, and AEs and concomitant medications
were documented. Patients were able to receive a bowel
regimen for the management of chronic opioid-related
constipation if necessary.
At 12 months or premature discontinuation (when a
patient discontinued from the study early), the study com-
pletion visit was carried out. At this visit, the BPI and glo-
bal evaluations were administered, AEs and concomitant
medications were documented, and a physical examina-
tion was done.
Statistical methods
All data from patients who had received at least 1 dose of
study medication were included in all efficacy and safety
analyses.
The primary efficacy measure was 5 questions of the BPI
assessing pain qualities in the past 7 days [47], which was
completed by the investigator in consultation with the
patient at baseline, each monthly visit, and study comple-
tion or early discontinuation. The following BPI end
points were investigated:
￿ Change from baseline in pain at its worst in the past 7
days (BPI question 3)
￿ Change from baseline in pain at its least in the past 7
days (BPI question 4)
Table 1: Criteria for patient selection
Inclusion criteria Exclusion criteria
Patients with chronic cancer pain who had successfully completed the 
previous equivalence study. Notably, patients were required to have 
been in dose-stable pain control in the last 2 days of the CR phase of the 
study
Pure or predominantly neuropathic pain or pain of unknown origin 
(where a mechanism or physical cause could not be identified)
Patients requiring at least 8 mg of hydromorphone every 24 hours for 
the management of chronic cancer pain
A recent (within the previous 6 months) or current history of drug and/
or alcohol abuse
Written informed consent Women of childbearing potential who were pregnant or lactating, 
seeking pregnancy, or failing to take adequate contraceptive precautions 
(i.e. abstinence, an oral contraceptive, a hormonal implant, an 
intrauterine device, or condoms/diaphragm and spermicide)
Intolerance of or hypersensitivity to hydromorphone or other opioids
Dysphagia
Vomiting judged by the investigator sufficient to interfere with oral 
analgesia
Any gastrointestinal disorder (except gastrointestinal cancers), including 
pre-existing severe gastrointestinal narrowing (pathologic or iatrogenic) 
that may have affected the absorption or transit of orally administered 
drugs, particularly the insoluble OROS® outer coating
Acute abdominal conditions that may have been obscured by opioids
Any significant central nervous system disorder including, but not limited 
to head injury, increased intracranial pressure, stroke within the 
previous 6 months, major clinical depression, and disorders of cognition 
which, in the opinion of the investigator, would interfere with the 
completion of patient assessments and study compliance 
(patients with stable cerebral metastases could be included)
Risk of serious decreases in blood pressure upon administration of an 
opioid analgesic 
(e.g. depleted blood volume, comprised vasomotor tone, circulatory 
shock)
Severe respiratory compromise or severely depressed ventilatory 
function, impaired renal or hepatic function, Addison's disease, 
hypothyroidism, prostatic hypertrophy, or urethral stricture which in 
the opinion of the investigator precluded the use of strong opioids
Receiving or received mono-amine oxidase inhibitors within the 
previous 2 weeks
Those previously entered into the study
Participation in another study with an investigational drug in the 
previous 4 weeks, or an analgesia study within the previous 8 weeks 
(with the exception of the equivalence study)BMC Palliative Care 2009, 8:14 http://www.biomedcentral.com/1472-684X/8/14
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￿ Change from baseline in pain on average (BPI question
5)
￿ Change from baseline in current pain (BPI question 6)
￿ Change from baseline in pain relief in the past 7 days
(BPI question 8)
BPI questions 3, 4, 5, and 6 were measured on a scale of 0
(no pain) to 10 (pain as bad as you can imagine); ques-
tion 8 was measured on a scale of 0% (no relief) to 100%
(complete relief).
Secondary efficacy measures were assessed monthly and at
study completion or early discontinuation. The first sec-
ondary efficacy measure was an evaluation of quality of
life (QoL) from question 9 of the BPI, analysed as change
from baseline in how pain has interfered with the
patient's life in the past 7 days. This question included 7
subsections: general activity, mood, walking ability, nor-
mal work, relationships, sleep, and enjoyment of life,
which were measured on a scale of 0 (does not interfere)
to 10 (completely interferes). Another secondary efficacy
measure was a global assessment of overall treatment
effectiveness completed by both the patient and the inves-
tigator separately. This was measured on a 5-point scale (1
= poor, 2 = fair, 3 = good, 4 = very good, 5 = excellent).
No formal statistical testing was done on the data; only
summary statistics were produced. For baseline and each
of the 12 monthly visits, absolute observed values were
used; whereas end point was calculated using the last
observation carried forward (LOCF) method.
Safety measures included monitoring of AEs, early discon-
tinuations, concomitant medications, and physical exam-
ination findings. GCP standards were followed to record
all AEs occurring during the study regardless of whether
they were considered to be related to the study drug. For-
mal definitions of AEs and questionnaires were not used.
AEs were coded using the Medical Dictionary for Regula-




68 patients were enrolled into the study (Belgium, n = 14;
Canada, n = 7; France, n = 2; Germany, n = 2; Netherlands,
n = 22; Spain, n = 7; UK, n = 14). 35 patients had been tak-
ing OROS® hydromorphone and 33 had been taking CR
morphine sulphate in the previous equivalence study. 10
patients (14.7%) completed the 1-year study, 4 patients
(11.4%) who had previously been taking OROS® hydro-
morphone and 6 patients (18.2%) who had been taking
CR morphine. The reasons for not completing the study
are shown in Table 2; the most common reasons for not
completing were death (22.1% of patients) and progres-
sion of disease (20.6%). Only a small proportion discon-
tinued owing to lack of efficacy (11.8%). The rate and
reasons for the dropouts did not appear to be related to
prior therapy. The baseline demographics and clinical
characteristics of the study population were similar
between patients who had taken the two previous treat-
ments (Table 3).
Extent of exposure to study medication
During the study, for all patients, the mean (standard
deviation [SD]) duration of exposure to study medication
was 139 (129.9) days (range, 2.0 to 438 days). The mean
(SD) average daily consumption of OROS® hydromor-
phone was 43.7 (28.14) mg/day (range, 9.6 to 139.2 mg/
day). Each of these variables was slightly higher in
patients who received morphine in the previous study.
At the beginning of the study, 8 patients received doses of
≥ 64 mg (64 mg, n = 1; 72 mg, n = 4; 96 mg, n = 3); at end
Table 2: Patient disposition (overall and by previous treatment)
Treatment in previous study
Number (%) OROS® hydromorphone CR morphine Overall
Entered the study 35 (100) 33 (100) 68 (100)
Completed the study 4 (11.4) 6 (18.2) 10 (14.7)
Did not complete study 31 (88.6) 27 (81.8) 58 (85.3)
Reasons for not completing the study
Death 10 (28.6) 5 (15.2) 15 (22.1)
Progression of study disease 7 (20.0) 7 (21.2) 14 (20.6)
Adverse event 5 (14.3) 4 (12.1) 9 (13.2)
Lack of efficacy 4 (11.4) 4 (12.1) 8 (11.8)
Protocol violation 3 (8.6) 4 (12.1) 7 (10.3)
Withdrawal of consent 1 (2.9) 2 (6.1) 3 (4.4)
Administrative reason 1 (2.9) 1 (3.0) 2 (2.9)
CR, controlled-releaseBMC Palliative Care 2009, 8:14 http://www.biomedcentral.com/1472-684X/8/14
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point, this increased to 20 patients (64 mg, n = 2; 72 mg,
n = 4; 80 mg, n = 3; 96 mg, n = 6; and n = 1 each for 112,
128, 168, 176, and 192 mg).
Efficacy results
Primary efficacy end point
Pain control was maintained during the year with
repeated once-daily dosing of OROS® hydromorphone.
Table 4 shows the mean scores at baseline and end point
for BPI items pain at its worst, pain at its least, pain on
average, pain right now, and pain relief. When looking at
the change in scores during the course of the study, pain
at its least, pain on average, and current pain scores were
maintained at a mild severity and worst pain scores fluc-
tuated between mild and moderate severity throughout
the 1-year study (Figure 1). Although scores were main-
tained at similar levels throughout the study, the mean
scores were slightly increased, i.e. worsened, at end point
compared with baseline. Pain relief also remained fairly
stable throughout the study (Figure 2), with mean (SD)
scores of 72.2% (22.8%) and 59.8% (27.6%) at baseline
and end point, respectively.
Secondary efficacy end points
Mean BPI pain interference scores remained stable during
the study, increasing only slightly from baseline to end
point for each of the QoL items (general activity, mood,
walking ability, normal work, relationships, sleep, and
enjoyment of life). BPI pain interference scores at baseline
and end point for all patients are shown in Figure 3. The
pain interference results by treatment in the previous
equivalence study generally reflected the overall results
and there were no major differences between patients who
had previously received OROS® hydromorphone and CR
morphine.
Mean patient and investigator global evaluation scores of
overall treatment effectiveness also remained generally
Table 3: Baseline demographic and clinical characteristics (overall and by previous treatment)







Mean (SD) age, years 57.4 (15.24) 58.3 (10.05) 57.8 (12.89)
Sex, n (%)
Male 9 (25.7) 16 (48.5) 25 (36.8)
Female 26 (74.3) 17 (51.5) 43 (63.2)
Race, n (%)
White 35 (100.0) 32 (97.0) 67 (98.5)
Asian 0 1 (3.0) 1 (1.5)
Mean (SD) height, cm 165.9 (8.32) 168.2 (10.76) 167.0 (9.58)
Mean (SD) weight, kg 62.4 (16.09) 68.0 (9.90) 65.1 (13.60)
Mean (SD) BMI, kg/m2 22.8 (5.90) 24.2 (4.18) 23.5 (5.14)
Cancer type, n (%)
Breast 11 (31.4) 12 (36.4) 23 (33.8)
Gastrointestinal 9 (25.7) 5 (15.2) 14 (20.6)
Genitourinary 5 (14.3) 3 (9.1) 8 (11.8)
Lung 5 (14.3) 7 (21.2) 12 (17.6)
Oral cavity 1 (2.9) 1 (3.0) 2 (2.9)
Other 4 (11.4) 5 (15.2) 9 (13.2)
Location of metastases, n (%)1 57 (100) 58 (100) 115 (100)
Bone 16 (28.1) 20 (34.5) 36 (31.3)
Bone marrow 1 (1.8) 1 (1.7) 2 (1.7)
Brain 1 (1.8) 2 (3.4) 3 (2.6)
Kidney 1 (1.8) 0 1 (0.9)
Liver 9 (15.8) 9 (15.5) 18 (15.7)
Lung 6 (10.5) 6 (10.3) 12 (10.4)
Lymph node 8 (14.0) 6 (10.3) 14 (12.2)
None 4 (7.0) 7 (12.1) 11 (9.6)
Other 11 (19.3) 7 (12.1) 18 (15.7)
Predominant pain type, n (%)
Bone or soft tissue 22 (62.9) 26 (78.8) 48 (70.6)
Mixed 6 (17.1) 3 (9.1) 9 (13.2)
Visceral 7 (20.0) 4 (12.1) 11 (16.2)
1shows total number of metastases; patients may be counted in more than one metastasis location
BMI, body mass index; CR, controlled-release; SD, standard deviationBMC Palliative Care 2009, 8:14 http://www.biomedcentral.com/1472-684X/8/14
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Table 4: BPI scores at baseline and end point (overall and by previous treatment)









Pain at its worst1
Baseline 4.3 (2.30) 5.1 (2.78) 4.7 (2.57)
End point 5.9 (2.58) 5.8 (2.98) 5.9 (2.76)
Pain at its least1
Baseline 1.3 (1.23) 1.8 (1.91) 1.6 (1.62)
End point 2.2 (1.81) 2.4 (2.43) 2.3 (2.12)
Pain on average1
Baseline 2.8 (1.89) 3.2 (2.10) 3.0 (2.00)
End point 3.9 (2.30) 3.8 (2.50) 3.9 (2.38)
Current pain1
Baseline 1.8 (1.84) 2.5 (2.21) 2.2 (2.05)
End point 3.3 (2.86) 3.5 (2.49) 3.4 (2.67)
Pain relief2
Baseline 74.4 (22.13) 70.0 (23.56) 72.2 (22.78)
End point 61.5 (27.40) 58.2 (28.11) 59.8 (27.60)
Baseline = absolute values; end point = last observation carried forward
10 = no pain, 10 = pain as bad as you can imagine; 20% to 100%
BPI, brief pain inventory; CR, controlled-release; SD, standard deviation
BPI questions 3, 4, 5, and 6: summary from baseline to subsequent months and end point (all patients) Figure 1
BPI questions 3, 4, 5, and 6: summary from baseline to subsequent months and end point (all patients). Baseline 
and months 1 to 12 = absolute values; end point = last observation carried forward. Participating patient numbers - pain at its 
worst: n = 65 at baseline, n = 10 at month 12, and n = 67 at end point; pain at its least: n = 66 at baseline, n = 10 at month 12, 
and n = 67 at end point; pain on average: n = 66 at baseline, n = 10 at month 12, and n = 67 at end point; current pain: n = 66 
at baseline, n = 10 at month 12, and n = 67 at end point. BPI, brief pain inventory; SE, standard error.BMC Palliative Care 2009, 8:14 http://www.biomedcentral.com/1472-684X/8/14
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stable from baseline to end point (Figure 4). Treatment
effectiveness was rated as fair to good throughout the
study.
Safety results
Overall, 63 patients (92.6%) reported AEs during the
study, 34 patients (97.1%) who had received OROS®
hydromorphone in the previous equivalence study and 29
patients (87.9%) who had received CR morphine. The
most commonly reported AEs, with at least a 10% inci-
dence, were nausea, constipation, vomiting, anaemia,
peripheral oedema, dyspnoea, asthenia, disease progres-
sion, somnolence, and urinary tract infection. AEs
reported in at least 5% of patients are shown in Table 5.
Most AEs were considered mild or moderate in severity,
approximately 25% of all reported AEs were considered
severe. Severe AEs were reported by 43 patients (63.2%),
and severe AEs considered related to study treatment were
reported by 11 patients (16.2%). 36 patients (52.9%)
reported AEs that were considered related to study treat-
ment (20 patients [57.1%] who had received OROS®
hydromorphone in the previous equivalence study and 16
patients [48.5%] who had received CR morphine). Of the
most common AEs (= 10% incidence in a treatment
group), some cases of nausea (11/24), constipation (18/
22), vomiting (7/15), and somnolence (6/8) were consid-
ered related to study treatment. In addition, all cases of
dry mouth were considered related to study treatment as
well as several cases of confusional state, anxiety, and
insomnia. None of the reports of diarrhoea or headache
was considered related to study treatment.
19 patients died either during or after the study. The rela-
tionship to treatment of the AEs leading to death was con-
sidered unlikely in 2 cases and unrelated in the other 17
cases. In addition to the deaths, other serious adverse
events (SAEs) were reported by 32 patients, the majority
of which were considered unrelated or unlikely to be
related to study medication. 8 patients (11.8%) had SAEs
that were considered to be possibly, probably, or defi-
nitely related to study treatment; these were: nausea and
vomiting in 2 patients; dehydration, malaise, nausea (2
episodes), pain, and vomiting (2 episodes) in 1 patient;
faecaloma in 1 patient; dizziness and nausea in 1 patient;
restlessness in 1 patient; suicide attempt in 1 patient; and
confusional state, hallucination, and pain in 1 patient.
BPI pain relief: summary from baseline to subsequent months and end point (overall and by previous treatment) Figure 2
BPI pain relief: summary from baseline to subsequent months and end point (overall and by previous treat-
ment). Baseline and months 1 to 12 = absolute values; end point = last observation carried forward. Participating patient num-
bers - OROS® hydromorphone: n = 32 at baseline, n = 4 at month 12, and n = 33 at end point; CR morphine: n = 32 at 
baseline, n = 6 at month 12, and n = 33 at end point; overall: n = 64 at baseline, n = 10 at month 12, and n = 66 at end point. 
BPI, brief pain inventory; CR, controlled-release; SE, standard error.BMC Palliative Care 2009, 8:14 http://www.biomedcentral.com/1472-684X/8/14
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The faecaloma and suicide attempt events were consid-
ered to have a definite relationship to study treatment.
9 patients (13.2%) had at least 1 AE that led to early dis-
continuation of the patient from the study; the majority of
these were considered probably related to study medica-
tion.
No clinically significant changes in any of the other safety
measures occurred during the study. The most commonly
used concomitant medications were the anti-inflamma-
tory dexamethasone (n = 55, 80.9%), the antiemetic
metoclopramide (n = 36, 52.9%), and the diuretic furo-
semide (n = 25, 36.8%).
Discussion
Chronic cancer pain is a highly prevalent condition.
Although opioid analgesics are known to be effective for
chronic moderate-to-severe pain in the short-term, data
on their long-term use is more limited. Understanding the
effects of long-term exposure to opioids has become par-
ticularly important in recent years as the life expectancy of
cancer patients increases owing to improved oncological
treatments.
CR opioid formulations are advocated for the manage-
ment of chronic cancer pain because they can provide
more consistent, around-the-clock pain relief with
decreased dosing frequency (once- or twice-daily). OROS®
hydromorphone may be particularly well suited to the
long-term management of cancer pain because it provides
consistent plasma concentrations, sustained analgesia,
and convenient once-daily dosing. In this open-label, sin-
gle treatment extension study, OROS® hydromorphone
was administered to patients with moderate-to-severe
chronic cancer pain who had successfully completed a
previous short-term equivalence study and whose pain
was controlled with a stable dose of medication. Prior opi-
oid therapy in the previous equivalence study (OROS®
hydromorphone versus CR morphine) did not affect clin-
ical outcomes such as efficacy or safety in this study.
The results demonstrate that pain control achieved with
OROS® hydromorphone is maintained for up to 1 year
with repeated once-daily dosing in patients with chronic
cancer pain. This was shown using a variety of measures,
including the BPI items pain at its worst, pain at its least,
pain on average, current pain, and pain relief, and patient
and investigator global evaluations of overall treatment
effectiveness. Throughout the study, pain scores were
maintained at mild to moderate levels. These results sup-
port short-term studies of OROS® hydromorphone for
chronic cancer pain [20-22,34]. In addition, the degree to
which patients' cancer pain interfered with their general
activity, mood, ability to walk, work, relationships, sleep,
and enjoyment of life was also maintained, suggesting
BPI pain interference scores at baseline and end point (all patients) Figure 3
BPI pain interference scores at baseline and end point (all patients). BPI scored from 0 = does not interfere to 10 = 
completely interferes. BPI, brief pain inventory.BMC Palliative Care 2009, 8:14 http://www.biomedcentral.com/1472-684X/8/14
Page 10 of 13
(page number not for citation purposes)
that there was no worsening of QoL during the year. This
has been demonstrated before; previous studies have
shown a positive impact on QoL with CR opioid formula-
tions [11,48]. There were no clear differences in the results
when comparing patients who had received OROS®
hydromorphone or CR morphine in the previous equiva-
lence study. Although most efficacy measures were main-
tained at similar levels throughout the study, for most
measures, the mean scores were slightly worsened at end
point compared with baseline. However, owing to the
progressive nature of the disease, some deterioration is to
be expected.
The most commonly reported AEs, with an incidence of at
least 10%, were nausea, constipation, vomiting, anaemia,
peripheral oedema, dyspnoea, asthenia, disease progres-
sion, somnolence, and urinary tract infection. These are
events typically seen with the use of strong opioids or in a
chronic cancer pain population. Slightly more AEs overall
and AEs considered related to study treatment were
reported in patients who had previously received OROS®
hydromorphone compared with CR morphine in the
equivalence study; however, the clinical significance of
this difference is questionable because of the degree and
nature of AEs expected in an advanced cancer population.
In addition, the majority of AEs were mild or moderate in
severity. 19 patients died either during or after the study.
There were slightly more deaths in patients treated with
OROS® hydromorphone compared with morphine in the
previous equivalence study; however, all deaths were con-
sidered unrelated or unlikely to be related to study treat-
ment. The occurrence of these deaths was not unexpected
given the severity of patients' conditions and the progres-
sive nature of the disease. Of the 32 patients who reported
other SAEs, the majority of the events were considered
unrelated or unlikely to be related to study treatment. 8
patients had SAEs that were considered to have a possible,
probable, or definite relationship to study treatment. 9
patients reported AEs that led to early discontinuation
from the study, and most of these AEs were considered
probably related to study treatment. In conclusion,
OROS® hydromorphone was found to be safe and reason-
ably well tolerated in this extension study.
There are a number of limitations of this study, which
may affect the interpretation of the results. This was an
open-label, uncontrolled study, so the results cannot be
directly compared to either no therapy or other opioid
therapies. A large number of patients (58/68; 85.3%) did
not complete the study. However, this is not unexpected
given the severity and progressive nature of the disease; in
fact, a large number of patients did not complete the study
owing to death (n = 15) and progression of disease (n =
14). Dropouts due to lack of efficacy were uncommon (n
= 8), but were to be expected given the progression of can-
cer. A further limitation was that no formal statistical anal-
Patient and investigator global evaluations at month 1 and end point (overall and by previous treatment) Figure 4
Patient and investigator global evaluations at month 1 and end point (overall and by previous treatment). Scale: 
0 = poor, 2 = fair, 3 = good, 4 = very good, 5 = excellent. CR, controlled-release.BMC Palliative Care 2009, 8:14 http://www.biomedcentral.com/1472-684X/8/14
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yses were done on the data. This was an open-label, single
treatment arm trial mainly assessing the safety of long-
term usage and secondary maintenance of efficacy; there-
fore, all analyses were done descriptively. End point was
calculated using the LOCF method, a method that
involves extrapolating the last observed measurement for
the patient. This method was necessary because the study
involved multiple visits and a critically ill patient popula-
tion, and therefore a high number of dropouts was
expected.
In spite of these limitations, this study has provided useful
insights into the effectiveness of the long-term use of
OROS® hydromorphone for relief of cancer pain, which
may be applicable to clinical practice. It also suggests that
conversion from previous opioid therapy to OROS®
hydromorphone is feasible without loss of pain control.
The effective morphine to hydromorphone conversion
ratio varies from 4:1 to 8:1 in different publications
[9,33,49-53]. A 5:1 morphine equivalents to hydromor-
phone conversion ratio is most often cited in the literature
[21,22,34,43-46] and was found to be clinically useful in
this study. The study population represents a rather small
selected subgroup of patients, i.e. with advanced cancer
and moderate-to-severe chronic cancer pain; nevertheless,
the analgesia provided by OROS®  hydromorphone is
maintained to some extent for up to a year, and the study
will be useful in the development of other long-term stud-
ies of OROS® hydromorphone.
Conclusion
The results of this open-label, single treatment, extension
study shows that long-term treatment with OROS® hydro-
morphone is beneficial in the management of persistent,
moderate-to-severe pain in patients with cancer.
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Table 5: Adverse events reported by at least 5% of patients (overall and by previous treatment)







Adverse event Number (%) of patients with adverse event
Nausea 13 (37.1) 11 (33.3) 24 (35.3)
Constipation 13 (37.1) 9 (27.3) 22 (32.4)
Vomiting 8 (22.9) 7 (21.2) 15 (22.1)
Anaemia 7 (20.0) 5 (15.2) 12 (17.6)
Peripheral oedema 5 (14.3) 6 (18.2) 11 (16.2)
Dyspnoea 4 (11.4) 5 (15.2) 9 (13.2)
Asthenia 4 (11.4) 5 (15.2) 9 (13.2)
Somnolence 6 (17.1) 2 (6.1) 8 (11.8)
Disease progression 6 (17.1) 2 (6.1) 8 (11.8)
Urinary tract infection 4 (11.4) 3 (9.1) 7 (10.3)
Headache 4 (11.4) 2 (6.1) 6 (8.8)
Diarrhoea 5 (14.3) 1 (3.0) 6 (8.8)
Back pain 4 (11.4) 1 (3.0) 5 (7.4)
Anorexia 3 (8.6) 2 (6.1) 5 (7.4)
Oedema 3 (8.6) 2 (6.1) 5 (7.4)
Dehydration 0 5 (15.2) 5 (7.4)
Confusional state 4 (11.4) 1 (3.0) 5 (7.4)
Pyrexia 4 (11.4) 1 (3.0) 5 (7.4)
Pain 1 (2.9) 4 (12.1) 5 (7.4)
Insomnia 1 (2.9) 3 (9.1) 4 (5.9)
Dry mouth 2 (5.7) 2 (6.1) 4 (5.9)
Anxiety 3 (8.6) 1 (3.0) 4 (5.9)
CR, controlled-releaseBMC Palliative Care 2009, 8:14 http://www.biomedcentral.com/1472-684X/8/14
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